Homology Medicines Stock Earnings Per Share
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
Homology Medicines fundamentals help investors to digest information that contributes to Homology Medicines' financial success or failures. It also enables traders to predict the movement of Homology Stock. The fundamental analysis module provides a way to measure Homology Medicines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Homology Medicines stock.
Homology |
Homology Medicines Company Earnings Per Share Analysis
Homology Medicines' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Homology Medicines Earnings Per Share | (35.10) X |
Most of Homology Medicines' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Homology Medicines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Homology Medicines has an Earnings Per Share of -35.1 times. This is 519.35% lower than that of the Biotechnology sector and notably higher than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Homology Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Homology Medicines' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Homology Medicines could also be used in its relative valuation, which is a method of valuing Homology Medicines by comparing valuation metrics of similar companies.Homology Medicines is currently under evaluation in earnings per share category among its peers.
Homology Fundamentals
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (78.85) % | |||
| Current Valuation | (27 M) | |||
| Shares Outstanding | 3.23 M | |||
| Shares Owned By Insiders | 9.20 % | |||
| Shares Owned By Institutions | 46.75 % | |||
| Number Of Shares Shorted | 338.72 K | |||
| Price To Earning | (10.00) X | |||
| Price To Book | 0.04 X | |||
| Price To Sales | 2.61 X | |||
| Revenue | 1.16 M | |||
| Gross Profit | (95.14 M) | |||
| EBITDA | (91.52 M) | |||
| Net Income | (112.96 M) | |||
| Cash And Equivalents | 201.07 M | |||
| Cash Per Share | 3.50 X | |||
| Total Debt | 1.32 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 8.44 X | |||
| Book Value Per Share | 22.65 X | |||
| Cash Flow From Operations | (96.23 M) | |||
| Short Ratio | 0.62 X | |||
| Earnings Per Share | (35.10) X | |||
| Price To Earnings To Growth | 21.38 X | |||
| Target Price | 1.5 | |||
| Beta | -0.11 | |||
| Market Capitalization | 3.02 M | |||
| Total Asset | 306.12 M | |||
| Retained Earnings | (542.1 M) | |||
| Working Capital | 72.34 M | |||
| Current Asset | 48.82 M | |||
| Current Liabilities | 8.27 M | |||
| Net Asset | 306.12 M |
About Homology Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Homology Medicines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Homology Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Homology Medicines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |